These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 620500)

  • 1. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias.
    Pippard MJ; Callender ST; Weatherall DJ
    Clin Sci Mol Med; 1978 Jan; 54(1):99-106. PubMed ID: 620500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1977 Oct; 2(8041):737-9. PubMed ID: 71542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of iron loading in transfusion-dependent thalassaemia.
    Pippard MJ; Letsky EA; Callender ST; Weatherall DJ
    Lancet; 1978 Jun; 1(8075):1178-81. PubMed ID: 77945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excretion of iron in response to deferoxamine in sickle cell anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):659-62. PubMed ID: 633013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E; Marcopito LF; Zago MA
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD; Cooper B; Rufo RR; Nienhuis AW; Anderson WF; Bunn HF; Rosenthal A; Nathan DG
    N Engl J Med; 1977 Aug; 297(8):418-23. PubMed ID: 882111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrioxamine-induced iron excretion in humans.
    Pippard MJ
    Baillieres Clin Haematol; 1989 Apr; 2(2):323-43. PubMed ID: 2660931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.
    Llados i Vallory EA; Girot R; Lenoir G; Payet M; Houze P; Bourdon R
    Eur J Pediatr; 1989 Apr; 148(6):503-6. PubMed ID: 2744011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).
    Pippard MJ; Jackson MJ; Hoffman K; Petrou M; Modell CB
    Scand J Haematol; 1986 May; 36(5):466-72. PubMed ID: 3738427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.